Published in Antimicrob Agents Chemother on October 01, 1982
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother (1983) 21.48
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother (1985) 11.34
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother (1984) 7.14
Fluoroquinolone antimicrobial agents. Clin Microbiol Rev (1989) 6.45
Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother (1986) 6.03
Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother (1992) 4.43
In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother (1989) 4.38
In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother (1988) 4.03
In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone. Antimicrob Agents Chemother (1986) 3.98
In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother (1992) 3.88
In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother (1987) 3.84
Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli. Antimicrob Agents Chemother (1986) 3.69
In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother (1988) 3.52
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative. Antimicrob Agents Chemother (1986) 3.38
Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant. J Bacteriol (1987) 3.04
Structure-activity relationships of the fluoroquinolones. Antimicrob Agents Chemother (1989) 2.63
In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother (1993) 2.61
Activities of new quinoline derivatives against genital pathogens. Antimicrob Agents Chemother (1985) 2.51
Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1989) 2.36
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother (1992) 2.32
In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1986) 2.29
Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620. Antimicrob Agents Chemother (1986) 2.26
In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother (1993) 2.18
In vitro activity of CI-934, a quinolone carboxylic acid active against gram-positive and -negative bacteria. Antimicrob Agents Chemother (1985) 2.13
Inhibition of DNA gyrase by optically active ofloxacin. Antimicrob Agents Chemother (1987) 2.03
In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. Antimicrob Agents Chemother (1986) 2.02
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620. Antimicrob Agents Chemother (1985) 1.99
In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother (1994) 1.96
Purification of Citrobacter freundii DNA gyrase and inhibition by quinolones. Antimicrob Agents Chemother (1988) 1.93
Inhibition by quinolones of DNA gyrase from Staphylococcus aureus. Antimicrob Agents Chemother (1991) 1.93
In vitro antibacterial activity of Q-35, a new fluoroquinolone. Antimicrob Agents Chemother (1992) 1.91
In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrob Agents Chemother (1992) 1.90
Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrob Agents Chemother (1988) 1.88
Antimycoplasmal activity of ofloxacin (DL-8280). Antimicrob Agents Chemother (1983) 1.86
In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents. Antimicrob Agents Chemother (1986) 1.79
Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria. Antimicrob Agents Chemother (1984) 1.77
DNA gyrase of Staphylococcus aureus and inhibitory effect of quinolones on its activity. Antimicrob Agents Chemother (1988) 1.60
Uptake and intracellular activity of an optically active ofloxacin isomer in human neutrophils and tissue culture cells. Antimicrob Agents Chemother (1990) 1.51
In vivo evaluation of NM441, a new thiazeto-quinoline derivative. Antimicrob Agents Chemother (1991) 1.49
Multicenter randomized study of single-dose ofloxacin versus amoxicillin-probenecid for treatment of uncomplicated gonococcal infection. Antimicrob Agents Chemother (1989) 1.41
Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus. Antimicrob Agents Chemother (1989) 1.39
Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats. Antimicrob Agents Chemother (1988) 1.37
In vitro evaluation of A-56619 and A-56620, two new quinolones. Antimicrob Agents Chemother (1986) 1.36
In vitro activity of HSR-903, a new quinolone. Antimicrob Agents Chemother (1997) 1.36
Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother (1989) 1.34
Proposed disk diffusion susceptibility criteria for ofloxacin. J Clin Microbiol (1985) 1.32
Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1991) 1.32
Ofloxacin pharmacokinetics in renal failure. Antimicrob Agents Chemother (1987) 1.27
Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother (1984) 1.26
In vitro antibacterial activity of a new quinolone, NM394. Antimicrob Agents Chemother (1991) 1.25
Anti-Mycobacterium avium activity of quinolones: in vitro activities. Antimicrob Agents Chemother (1993) 1.23
Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis. Antimicrob Agents Chemother (1989) 1.22
In vitro activity of amifloxacin against outer membrane mutants of the family Enterobacteriaceae and frequency of spontaneous resistance. Antimicrob Agents Chemother (1989) 1.22
Clinical isolate of Citrobacter freundii highly resistant to new quinolones. Antimicrob Agents Chemother (1988) 1.19
[Respiratory tract infections--clinical results with ofloxacin]. Infection (1986) 1.18
In vitro and in vivo activities of QA-241, a new tricyclic quinolone derivative. Antimicrob Agents Chemother (1989) 1.11
In vitro and in vivo antibacterial activities of CFC-222, a novel broad spectrum fluoroquinolone. Drugs (1995) 1.09
Inhibition of theophylline clearance by coadministered ofloxacin without alteration of theophylline effects. Antimicrob Agents Chemother (1987) 1.08
Effect of oral ofloxacin on fecal bacteria in human volunteers. Antimicrob Agents Chemother (1987) 1.07
In vitro and in vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin). Antimicrob Agents Chemother (1985) 1.07
Mechanism of differential activities of ofloxacin enantiomers. Antimicrob Agents Chemother (1996) 1.07
Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother (1991) 1.07
In vitro activities of ofloxacin and four other new quinoline-carboxylic acids against Chlamydia trachomatis. Antimicrob Agents Chemother (1988) 1.03
Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria. J Clin Microbiol (1989) 1.02
In vitro antibacterial activity of DU-6859a, a new fluoroquinolone. Antimicrob Agents Chemother (1995) 1.02
Comparison of ofloxacin, gentamicin, and tobramycin concentrations in tears and in vitro MICs for 90% of test organisms. Antimicrob Agents Chemother (1990) 1.01
Antibacterial activity of ofloxacin and its mode of action. Infection (1986) 1.01
Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother (1986) 1.00
Ofloxacin compared with chloramphenicol in the management of external ocular infection. Br J Ophthalmol (1991) 1.00
In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent. Antimicrob Agents Chemother (1993) 1.00
Concentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally. Antimicrob Agents Chemother (1989) 0.99
Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria. Antimicrob Agents Chemother (1992) 0.97
Reduced susceptibilities of Shigella sonnei strains isolated from patients with dysentery to fluoroquinolones. Antimicrob Agents Chemother (1993) 0.97
Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent. Antimicrob Agents Chemother (1990) 0.96
Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide. Antimicrob Agents Chemother (1993) 0.95
Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice. Infection (1986) 0.95
Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Antimicrob Agents Chemother (1993) 0.95
Clinical efficacy of ofloxacin in lower respiratory tract infections. A multicentre study. Drugs (1987) 0.94
Activity of quinolones against mycobacteria. Drugs (1995) 0.94
Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia. Antimicrob Agents Chemother (1987) 0.88
Disk susceptibility of ofloxacin, a new carboxyquinolone. J Clin Microbiol (1985) 0.86
Comparative in vitro antibacterial activity of ofloxacin and ciprofloxacin against some selected gram-positive and gram-negative isolates. Infection (1986) 0.86
Topical ofloxacin compared with gentamicin in the treatment of external ocular infection. Ofloxacin Study Group. Br J Ophthalmol (1992) 0.86
In vitro and in vivo antibacterial activities of KB-5246, a new tetracyclic quinolone. Antimicrob Agents Chemother (1989) 0.85
Effect of ofloxacin combined with Lactobacillus casei against Mycobacterium fortuitum infection induced in mice. Antimicrob Agents Chemother (1990) 0.83
E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. Antimicrob Agents Chemother (1995) 0.82
Uptake and intracellular activity of NM394, a new quinolone, in human polymorphonuclear leukocytes. Antimicrob Agents Chemother (1996) 0.82
A multicenter study on clinical efficacy of ofloxacin in respiratory and urinary tract infections. Infection (1986) 0.79
Efficacy of ofloxacin in uncomplicated gonorrhoea. Infection (1986) 0.77
Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients. Infection (1986) 0.77
Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. Antimicrob Agents Chemother (2001) 0.75
Emergence of fluoroquinolone resistance in Bacteroides fragilis accompanied by resistance to beta-lactam antibiotics. Antimicrob Agents Chemother (1988) 0.75
Intraoperative concentrations of ofloxacin in serum, bile fluid, and gallbladder wall tissue. Antimicrob Agents Chemother (1990) 0.75
Global and regional cerebral metabolic rate of 2-[18F]fluoro-2-deoxy-D-glucose in the presence of ofloxacin, a gamma-aminobutyric acid a receptor antagonist. Antimicrob Agents Chemother (1991) 0.75
NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients. Drugs (1995) 0.75
Ofloxacin: clinical evaluation in urinary and respiratory infections. Infection (1986) 0.75
Diffusion of oral ofloxacin (HOE 280) into human prostatic tissue: assessment by an improved high-performance liquid chromatographic method. Infection (1986) 0.75
In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother (1980) 26.28
Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae. Antimicrob Agents Chemother (1981) 11.11
Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties. Antimicrob Agents Chemother (1975) 8.67
Changing ecology of bacterial infections as related to antibacterial therapy. J Infect Dis (1970) 7.72
In vitro antibacterial activity of norfloxacin (MK-0366). Antimicrob Agents Chemother (1982) 6.97
Cinoxacin: in vitro antibacterial studies of a new synthetic organic acid. Antimicrob Agents Chemother (1975) 5.49
Pseudomonas aeruginosa infections: persisting problems and current research to find new therapies. Ann Intern Med (1975) 5.00
In vitro and in vivo antibacterial activity of AB206, a new naphthyridine derivative. Antimicrob Agents Chemother (1980) 2.98
KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res (1999) 40.62
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother (1980) 26.28
Functional annotation of a full-length mouse cDNA collection. Nature (2001) 23.61
Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. J Am Coll Cardiol (2001) 12.56
Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein. Cell (1992) 10.78
Tree allometry and improved estimation of carbon stocks and balance in tropical forests. Oecologia (2005) 10.52
Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem (1996) 10.51
Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 A resolution. Nature (2000) 9.44
Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections. Antimicrob Agents Chemother (1981) 8.59
Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection (1984) 7.53
In vitro and in vivo antibacterial activity of T-1220, a new semisynthetic penicillin. Antimicrob Agents Chemother (1977) 7.35
Purification and properties of inducible penicillin beta-lactamase isolated from Pseudomonas maltophilia. Antimicrob Agents Chemother (1982) 7.11
Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1991) 7.10
CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet (1994) 7.07
Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to beta-lactam antibiotics in Staphylococcus aureus. J Bacteriol (1986) 6.97
Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J (1998) 6.65
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature (2000) 6.49
Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell (1994) 6.45
Baculovirus expression vectors: the requirements for high level expression of proteins, including glycoproteins. J Gen Virol (1987) 6.41
Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex. Science (1992) 6.35
Delineating developmental and metabolic pathways in vivo by expression profiling using the RIKEN set of 18,816 full-length enriched mouse cDNA arrays. Proc Natl Acad Sci U S A (2001) 6.07
Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother (1986) 6.03
Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother (1986) 6.00
Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol (1992) 5.93
The Arabidopsis ERECTA gene encodes a putative receptor protein kinase with extracellular leucine-rich repeats. Plant Cell (1996) 5.82
Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science (1997) 5.80
The purification and properties of penicillin beta-lactamases mediated by transmissible R factors in Escherichia coli. J Biochem (1969) 5.35
Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 4.96
Cloning of human, mouse and fission yeast recombination genes homologous to RAD51 and recA. Nat Genet (1993) 4.96
Organization of the recA gene of Escherichia coli. Proc Natl Acad Sci U S A (1980) 4.90
Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation (1983) 4.70
In vitro antibacterial activity of cefoperazone (T-1551), a new semisynthetic cephalosporin. Antimicrob Agents Chemother (1979) 4.49
The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med (1998) 4.48
Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother (1992) 4.43
In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother (1989) 4.38
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol (1988) 4.20
Purification and properties of a new beta-lactamase from Pseudomonas cepacia. Antimicrob Agents Chemother (1980) 4.09
In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother (1988) 4.03
Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A (1997) 3.88
In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother (1987) 3.84
Isolation of human rotavirus in cell cultures: brief report. Arch Virol (1981) 3.83
In vitro and in vivo antibacterial activity of AT-2266. Antimicrob Agents Chemother (1983) 3.80
Complex formation and functional versatility of Mre11 of budding yeast in recombination. Cell (1998) 3.80
Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med (1995) 3.74
Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli. Antimicrob Agents Chemother (1986) 3.69
Antibacterial activity of apalcillin (PC-904) against gram-negative bacilli, especially ampicillin-, carbenicillin-, and gentamicin-resistant clinical isolates. Antimicrob Agents Chemother (1978) 3.65
A DNA damage response pathway controlled by Tel1 and the Mre11 complex. Mol Cell (2001) 3.65
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation (1994) 3.63
Biochemical properties of beta-lactamase produced by Flavobacterium odoratum. Antimicrob Agents Chemother (1985) 3.62
Nucleotide sequence of the lexA gene of E. coli. Cell (1981) 3.61
Properties of novel beta-lactamase produced by Bacteroides fragilis. Antimicrob Agents Chemother (1983) 3.59
Interaction of Mre11 and Rad50: two proteins required for DNA repair and meiosis-specific double-strand break formation in Saccharomyces cerevisiae. Genetics (1995) 3.57
Studies on radiation-sensitive mutants of E. coli. I. Mutants defective in the repair synthesis. Mol Gen Genet (1968) 3.55
In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother (1988) 3.52
Defining the functions of trans-SNARE pairs. Nature (1998) 3.52
Induction of beta-lactamase by various beta-lactam antibiotics in Enterobacter cloacae. Antimicrob Agents Chemother (1980) 3.48
The decline in child mortality: a reappraisal. Bull World Health Organ (2000) 3.46
T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation (1999) 3.41
Plasmid-mediated penicillin beta-lactamases in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1976) 3.40
Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin- mediated cell-cell adhesion. Science (1998) 3.39
Variant of penicillinase mediated by an R factor in Escherichia coli. J Bacteriol (1970) 3.33
Breast cancer after exposure to the atomic bombings of Hiroshima and Nagasaki. N Engl J Med (1968) 3.29
Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev (1997) 3.23
Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nat Genet (1994) 3.17
In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. Antimicrob Agents Chemother (1987) 3.12
Cinemicrographic study of tissue cell cultures infected with Shigella flexneri. Jpn J Med Sci Biol (1968) 3.12
Determination of the ID50 values of antibacterial agents in agar. J Antibiot (Tokyo) (1978) 3.08
Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN12873. Antimicrob Agents Chemother (1984) 3.07
Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res (1993) 3.05
An essential gene, ESR1, is required for mitotic cell growth, DNA repair and meiotic recombination in Saccharomyces cerevisiae. Nucleic Acids Res (1994) 3.05
Drug resistance of enteric bacteria. XIV. Comparison of beta-lactamases in gram-negative rod bacteria resistant to alpha-aminobenzylpenicillin. Jpn J Microbiol (1968) 3.04
Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant. J Bacteriol (1987) 3.04
Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain. J Biol Chem (1977) 3.02
Studies on the pathogenicity of Yersinia enterocolitica. I. Experimental infection in rabbits. Microbiol Immunol (1977) 2.99
Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol (1997) 2.98
In vitro and in vivo antibacterial activity of AB206, a new naphthyridine derivative. Antimicrob Agents Chemother (1980) 2.98
Studies on the pathogenicity of Yersinia enterocolitica. II. Interaction with cultured cells in vitro. Microbiol Immunol (1977) 2.96
Characteristics of purified recA protein and the regulation of its synthesis in vivo. Cold Spring Harb Symp Quant Biol (1979) 2.93
Involvement of rho p21 in the GTP-enhanced calcium ion sensitivity of smooth muscle contraction. J Biol Chem (1992) 2.90